Nov 24, 2025 07:05AM
Nov 24, 2025 07:05AM
Aug 26, 2025 08:05AM
Jul 23, 2025 07:05AM
Jul 23, 2025 07:05AM
Jul 17, 2025 07:05AM
Jul 17, 2025 07:05AM Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
May 15, 2025 10:01AM
May 14, 2025 04:05PM
Mar 28, 2025 07:30AM
Mar 27, 2025 04:05PM
Mar 20, 2025 07:05AM
Mar 6, 2025 07:06AM
Mar 6, 2025 07:05AM Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
Feb 20, 2025 07:06AM
Feb 20, 2025 07:05AM
Jan 22, 2025 07:05AM
Jan 22, 2025 07:05AM
Nov 25, 2024 07:05AM
Nov 25, 2024 07:05AM
Nov 12, 2024 04:05PM Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Nov 7, 2024 09:05AM
Nov 7, 2024 09:05AM
Oct 22, 2024 07:05AM
Oct 22, 2024 07:05AM
Aug 12, 2024 04:05PM
Jul 29, 2024 04:05PM
Jul 11, 2024 07:07AM Clearside Biomedical (CLSD) Appoints Glenn Yiu to its Scientific Advisory Board
Jul 11, 2024 07:05AM
Jun 12, 2024 07:05AM
May 21, 2024 07:05AM
Mar 12, 2024 04:05PM
Nov 13, 2023 04:05PM
Nov 8, 2023 07:05AM
Nov 7, 2023 04:20PM Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting
Nov 3, 2023 12:00PM
Nov 2, 2023 07:05AM
Oct 4, 2023 09:00AM
Jul 10, 2023 07:06AM
Jul 10, 2023 07:05AM
May 11, 2023 07:05AM
Apr 27, 2023 07:05AM Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
Mar 9, 2023 04:05PM
Feb 6, 2023 07:36AM
Feb 6, 2023 07:30AM
Oct 4, 2022 07:06AM
Oct 4, 2022 07:05AM
Aug 9, 2022 07:05AM
Aug 8, 2022 04:30PM Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million
Jul 7, 2022 07:05AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All